NASDAQ$TVTX
Travere Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Travere Therapeutics reported third quarter financial results
Travere Therapeutics reported a net product sales of $50.8 million and total revenue of $53.5 million for the third quarter of 2022. The company's cash, cash equivalents and marketable securities totaled $506.3 million as of September 30, 2022. The EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe and a new PDUFA target action date for sparsentan in IgAN was set for February 17, 2023.
- EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023
- New PDUFA target action date for sparsentan in IgAN set for February 17, 2023
- Breakthrough Therapy Designation granted to pegtibatinase development program for classical homocystinuria (HCU)
- Cash, cash equivalents and marketable securities totaled $506.3 million
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$53.5M
Revenue by segment
Travere · $25.4M total across 1 segment · Q3 2022
- Tiopronin products$25.4M—100.0%
Forward guidance
Travere is focused on advancing its IgA nephropathy and FSGS programs, positioning sparsentan as a dual-acting, non-immunosuppressive treatment option for rare kidney disorders. The company anticipates potential approvals of sparsentan for IgA nephropathy in the U.S. and Europe next year and looks forward to the upcoming readout of the DUPLEX Study of sparsentan in FSGS in the first half of next year, as well as the potential to advance pegtibatinase into a pivotal trial for HCU in 2023.
Tailwinds
- Potential approvals of sparsentan for IgA nephropathy in the U.S. and Europe next year
- Upcoming readout of the DUPLEX Study of sparsentan in FSGS in the first half of next year
- Potential to advance pegtibatinase into a pivotal trial for HCU in 2023
- Built upon strong commercial foundation to establish a field team with extensive nephrology experience in the U.S.
- Advancing IgA nephropathy and FSGS programs
Headwinds
- Risk of FDA not granting accelerated approval of sparsentan for IgAN within the extended target action date
- Risk that the Phase 3 PROTECT Study of sparsentan in IgAN will not demonstrate that sparsentan is safe or effective
- Risk that the Phase 3 DUPLEX Study of sparsentan in FSGS will not demonstrate that sparsentan is safe or effective
- Risk that sparsentan will not be approved for efficacy, safety, regulatory or other reasons
- Risk that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro